In lieu of that, Elypta has developed the first-ever metabolism-based liquid biopsy platform, meant for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, and of course, exceptionally sensitive in studies to date and provides affordable assay technology. These features enable multiple potential applications of the platform that are explored across cancers. It helps in earlier detection of recurring cancer by safer, more convenient, and closer surveillance postsurgery at a time when the doctors are uncertain about the symptoms. The platform also acts as a guide for therapy by more accurate prognosis and closer monitoring of response to treatment.
Meanwhile, a major part of Elypta’s attention is focused on enabling a more accurate and efficient way to measure glycosaminoglycans. On that note, the company offers the first-of-its-kind standardized service for full spectrum glycosaminoglycan quantification using the Elypta MIRAM™ Glycosaminoglycan Kit (which is used for research use only).
Elypta: Augmenting the Scope of Cancer Detection
The Elypta MIRAM™ Glycosaminoglycan Kit also makes the most of established state-of-the-art lab methods meant for glycosaminoglycan (GAG) extraction and detection for delivering reliable performance in a standardized and scalable way. The method relies on an enzymatic digestion assay that depolymerizes GAGs into disaccharides. Subsequently, disaccharides are labelled and separated by ultra-high performance liquid chromatography (UHPLC) and are detected using electrospray ionization triple-quadrupole mass spectrometry (ESI-MS/MS) through multiple reaction monitoring (MRM).
Apart from encouraging academic researchers to further expand the boundaries of standardized analysis of glycosaminoglycans for their research using Elypta MIRAM™ Glycosaminoglycan Kits, the company helps researchers in fundamental research on the causal role of GAGs in cancer initiation, evolution, or progression or related research questions. Likewise, when it comes to pre-clinical research, the company makes room for researchers to assess the role of GAGs in animal, cellular, xenograft models of cancer or related research questions. Last but not least, Elypta also encourages researches in clinical research that comprises human exploratory or validation studies in cancer and the role of GAGs as biomarkers.
For cancer-related research, the company is always open to exploring collaborative opportunities and joining hands with other bright minds to eradicate the global malice that cancer has now become. Driven by this objective to reduce cancer mortality, Elypta is set to redefine the boundaries in cancer research—with its metabolism-based approach and robust, cost-efficient solutions.